楊中舟?臨床醫(yī)學(xué)人文研究中心,、醫(yī)學(xué)人文教研室
?
學(xué)術(shù)背景
2010-2014 中國海洋大學(xué)本科
2015-2022 香港大學(xué)公共衛(wèi)生學(xué)院博士
?2022-2024中山大學(xué)助理研究員：衛(wèi)生經(jīng)濟(jì)研究
2025-至今：安寧療護(hù)衛(wèi)生經(jīng)濟(jì)專職科研人員
?
研究方向
安寧療護(hù),、衛(wèi)生經(jīng)濟(jì),、臨床統(tǒng)計(jì),、感染性疾病
?
專業(yè)協(xié)會(huì)
廣東省安寧療護(hù)指導(dǎo)中心秘書,，廣東省衛(wèi)生經(jīng)濟(jì)學(xué)會(huì)常委,，全國高壓氧學(xué)會(huì)專家組成員,，歐洲臨床微生物與感染病學(xué)會(huì)會(huì)員。
?
科研成果
楊中舟博士,，從2010年確定人生方向,，到2024 年先后經(jīng)歷“學(xué)研”和“產(chǎn)用政”的兩個(gè)階段。博士畢業(yè)后致力于明確“政用產(chǎn)學(xué)研”各模塊的聚焦領(lǐng)域,，尤其是衛(wèi)生經(jīng)濟(jì)研究在醫(yī)療領(lǐng)域的全方位應(yīng)用,，先后在 International Journal of Infectious Diseases, Nature Communications，J Infect等國際頂尖和專業(yè)期刊上發(fā)表 SCI 論文 16余篇,，通訊/第一6 余篇,，作為分析人員發(fā)表參與作者文章10篇。目前借助政用產(chǎn)學(xué)研各界資源,，希望推動(dòng)本院的安寧療護(hù)科室與省指導(dǎo)中心的建設(shè),。研究領(lǐng)域包含以下三類：
?
衛(wèi)生經(jīng)濟(jì)轉(zhuǎn)化類
針對(duì)慢病患者診療費(fèi)用高昂，給患者家庭帶來的經(jīng)濟(jì)和精神雙重負(fù)擔(dān),，主要開展衛(wèi)生經(jīng)濟(jì)研究提升慢病患者的生存質(zhì)量和人文關(guān)懷,。
近期代表性成果：
1.? 會(huì)議論文：Zhongzhou Yang et al., ?A Cost-effectiveness Study for Palliative Care of Terminal-Stage Cancer Inpatients in China, APHC, 2025 Jan 21, Oral presentation, 安寧療護(hù)亞洲區(qū)頂級(jí)會(huì)議。
2.? 主持項(xiàng)目：國家科技信息資源綜合利用與公共服務(wù)中心STI數(shù)字醫(yī)療實(shí)驗(yàn)室,，藥物經(jīng)濟(jì)評(píng)估：臨床宏基因組檢測(cè)在呼吸道感染住院病人的應(yīng)用,，2024-10 至 2025-10, 4萬元, 編號(hào)2024STI068
3.? 協(xié)助發(fā)明專利：一種痛風(fēng)性關(guān)節(jié)炎診斷試劑盒及其應(yīng)用, 授權(quán)時(shí)間2023, 中國, CN202010425589.5
4.? 骨干成員：橫向課題，NIPT及mNGS診療價(jià)值及衛(wèi)生經(jīng)濟(jì)學(xué)評(píng)估, 2023-至今, 30萬元, 59000-71020008,，
5.? 大會(huì)報(bào)告：衛(wèi)生經(jīng)濟(jì)產(chǎn)業(yè)報(bào)告,，eHealth platform for cancer prevention and control: facilitate China-EU collaboration in biotechnology因研發(fā)eHealth平臺(tái)，應(yīng)邀作為2022年中歐生物產(chǎn)業(yè)大會(huì)主講嘉賓
?
針對(duì)?病毒性感染（如新冠和HPV）給中國經(jīng)濟(jì)和公共衛(wèi)生帶來巨大挑戰(zhàn),，主要搭建數(shù)學(xué)模型完善感染性疾病的監(jiān)測(cè)預(yù)警機(jī)制
近期代表性成果：
1.? Zhongzhou Yang et al., Total infectome characterization of respiratory infections during the period of 2022-23 COVID outbreak in China revealed extensive co-infections. Pathogens, 2024, 13(3), 216.
2.? Linlin Xie et al., Zhongzhou Yang et al., The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract. J Infect. 2024 Feb 9 doi: 10.1016/j.jinf.2024.01.017. (IF: 28.2)
3.? Zhongzhou Yang et al., The Lifestyle Factors of Physical Activity and Diet Balance associated with HPV Infection. Frontiers in Oncology, 2023 Dec 7 (IF: 5.8)
4.? Zhongzhou Yang et al., Vaginal microbiota and personal risk factors associated with HPV status conversion – a new approach to reduce the risk of cervical cancer? Plos One 2022 Aug 9;17(8):e0270521
5.? Zhongzhou Yang et al., Empirical estimation of the incubation period for hand-foot-and-mouth disease from school outbreaks. IJID 2016 53 (Supplement), 134. (IF: 12.1)
?
針對(duì)臨床復(fù)雜問題,，進(jìn)行統(tǒng)計(jì)分析建模
協(xié)助統(tǒng)計(jì)分析代表性成果：
1.? Andrew P. Hutchins, Zhongzhou Yang et al., Models of global gene expression define major domains of cell type and tissue identity Nucleic Acids Research 2017 45, No. 5 (IF: 19.2)
2.? Andrew P Hutchins et al., Zhongzhou Yang et al., Metabolic and epigenetic dysfunctions underlie the arrest of in vitro fertilized human embryos in a senescent-like state, PLOS Biology, 2022 Jun 30;20(6):e3001682? (IF: 9.8)
3.? Huanhuan Li et al., Zhongzhou Yang et al., RNA Helicase DDX5 Inhibits Reprogramming to Pluripotency by miRNA-Based Repression of RYBP and its PRC1-Dependent and -Independent Functions Cell Stem Cell 2017 20, 571(IF: 22)
4.? Qiang Zhuang et al., Zhongzhou Yang et al., NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming Nature Cell Biology 2018 20, 400-412 (IF: 20)?
5.? Huang et al., Zhongzhou Yang., JMJD3 acts in tandem with KLF4 to facilitate reprogramming to pluripotency, Nat Com, 2020 Oct 8;11(1):5061 (IF: 12.1)
?
工作關(guān)聯(lián)愛好
提升專注：臺(tái)球,，高爾夫
挑戰(zhàn)難題：皮劃艇（香港皮劃艇協(xié)會(huì)證書），立槳沖浪（香港沖浪協(xié)會(huì)證書）
知識(shí)科普：約2.5萬粉絲,，https://www.zhihu.com/people/zhong-zhou-37-56/activities
?
歡迎對(duì)衛(wèi)生經(jīng)濟(jì),、安寧療護(hù)、統(tǒng)計(jì)建模工作感興趣的合作方聯(lián)絡(luò),。
電子郵件：[email protected]